Advertisement

International Journal of Clinical Pharmacy

, Volume 33, Issue 1, pp 80–87 | Cite as

Importation of prescription medicines into New Zealand: a snapshot of intercepted products

  • Janie SheridanEmail author
  • Fiona Kelly
  • James Oughton
  • Aula Al-Jubbawey
  • Matthew Grey
  • Shameel Hussein
  • Edwardine Jayetileke
  • Mehul Mehta
  • Shriyash Nair
Research Article
  • 138 Downloads

Abstract

Objective The aim of this research was to describe the types of prescription medicines being imported into New Zealand. Setting Imported medicines intercepted at the international mail centre in Auckland and referred to the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) between July and December 2007 were studied. Method During the study 3,918 prescription medicine imports were intercepted and entered into a database by Medsafe. These were categorised according to the country the medicines were posted from and medicine related details such as brand, active ingredient(s), route of administration, strength and quantity imported. Researchers systematically categorised medicines by therapeutic indications, dosage form, whether these medicines were available in New Zealand and if they were subsidised by the New Zealand government. Main outcome measure Types of medicines imported into New Zealand and whether or not they were legally available and subsidised by the government. Results Medicines were most commonly imported from India and China. Seventy eight percent of the total medicines imported were already available in New Zealand, and of these almost half were subsidised by the government. Antibiotics contributed to a significant proportion of the total subsidised medicines imported, the most common being amoxicillin. Four of the five most commonly imported medicines could be considered ‘lifestyle’ medicines (sildenafil, tadalafil, finasteride and sibutramine). ‘High risk’ medicines were identified—for example medicines used in the treatment of tuberculosis, malignant diseases and mental health disorders. Conclusion This study is the first of its kind in New Zealand to explore the types of prescription medicines imported into the country. The majority of imported medicines were classified as ‘lifestyle’ medicines. The study findings also identified possible negative public health implications associated with some of the imported prescription medicines, for example resistance associated with the importation of antibiotics.

Keywords

Internet pharmacies Medicine misuse Medicines importation New Zealand Prescription 

Notes

Acknowledgments

We would like to acknowledge the support of staff at Medsafe in providing us with data and feedback on the final draft.

Conflicts of Interests

James Oughton is employed by Medsafe, which provided us with the data for this study. He reports no conflict of interests. The remaining authors note no conflict of interests.

References

  1. 1.
    Medsafe. New Zealand medicines and medical safety authority: about medsafe. 2008. www.medsafe.govt.nz. Last accessed 2 Nov 2010.
  2. 2.
    PHARMAC. About PHARMAC. 2008. http://www.pharmac.govt.nz/patients/AboutPHARMAC. Last accessed 2 Nov 2010.
  3. 3.
    Permanent Forum on International Pharmaceutical Crime. Who we are. 2010. Available from: http://www.pfipc.org/Who_We_Are.php. Last accessed 2 Nov 2010.
  4. 4.
    Weiss AM. Buying prescription drugs on the internet: promises and pitfalls. Cleve Clin J Med. 2006;73(3):282–8.PubMedCrossRefGoogle Scholar
  5. 5.
    National Audit Office. Safety, quality, efficacy: regulating medicines in the UK. London: The Stationery Office; 2003.Google Scholar
  6. 6.
    FDA. FDA warns consumers not to buy or use prescription drugs from various Canadian websites that apparently sell counterfeit products 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108722.htm. Last accessed 2 Nov 2010.
  7. 7.
    Bessell T, Silagy C, Anderson J, Hiller J, Sansom L. Quality of global e-pharmacies: can we safeguard consumers? Eur J Clin Pharmacol. 2002;58(9):567–72.PubMedCrossRefGoogle Scholar
  8. 8.
    George B, Emmanuel J, Middleton K. Overseas-based online pharmacies: a source of supply for illicit drug users. Med J Aust. 2004;180(3):118–9.Google Scholar
  9. 9.
    Diaz J, Griffith R, Ng J, Reinert S, Friedmann P, Moulton A. Patients’ use of the internet for medical information. J Gen Intern Med. 2002;17(3):180–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Eysenbach G, Powell J, Kuss O, Eun-Ryoung S. Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA. 2002;287(20):2691–700.PubMedCrossRefGoogle Scholar
  11. 11.
    Ministry of Transport. Land transport amendment act. Wellington: Ministry of Transport; 2009.Google Scholar
  12. 12.
    Peterson G, Aslani P, Williams K. How do consumers search for and appraise information on medicines on the internet? A qualitative study using focus groups. J Med Internet Res. 2003;5(4):e33.PubMedCrossRefGoogle Scholar
  13. 13.
    Bessell T, Anderson J, Silagy C, Sansom L, Hiller J. Surfing, self-medicating and safety: buying non-prescription and complementary medicines via the internet. Qual Saf Health Care. 2003;12(2):88–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Reeves D. The 2005 Garrod lecture: the changing access of patients to antibiotics—for better or worse? J Antimicrob Chemother. 2005;59(3):333–41.CrossRefGoogle Scholar
  15. 15.
    Raine C, Webb D, Maxwell S. The availability of prescription-only analgesics purchased from the internet in the UK. Br J Clin Psychol. 2008;67(2):250–4.Google Scholar
  16. 16.
    Cars O, Diaz-Hogberg L, Murray M, Nordberg O, Sivaraman S, Lundborg CS, et al. Meeting the challenge of antibiotic resistance. BMJ. 2008;337:726–8.CrossRefGoogle Scholar
  17. 17.
    Pharmaceutical Management Agency. New Zealand pharmaceutical schedule April 2007. Wellington: PHARMAC; 2007. ISSN 1172 9376.Google Scholar
  18. 18.
    BMJ and RPSGB. British National Formulary London: BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain; 2008. ISBN 9780853697787.Google Scholar
  19. 19.
    MIMS. MIMS Online. 2008. www.mims.co.nz. Last accessed 2 Nov 2010.
  20. 20.
    Sweetman S, editor. Martindale: the complete drug reference. London: Pharmaceutical Press; 2007. ISBN: 085369687X.Google Scholar
  21. 21.
    Kloner R, Zusman Z. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol. 1999;84(5(supp)):11–7.CrossRefGoogle Scholar
  22. 22.
    Santtila P, Jern P, Varjonen M, Witting W, von der Pahlen B. Recreational use of erectile dysfunction medication may decrease confidence in ability to gain and hold erections in young males. Int J Impot Res. 2007;19(6):586–91.CrossRefGoogle Scholar
  23. 23.
    European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500069995.pdf. Last accessed 2 Nov 2010.
  24. 24.
    Medsafe. Media releases. Withdrawal of sibutramine (Reductil) in New Zealand. http://medsafe.govt.nz/hot/media/2010/sibutramineoct2010.asp. Last accessed 3 Dec 2010.
  25. 25.
    Schoen C, Osborn R, Huynh PT, Doty M, Davis K, Zapert K, et al. Primary care and health system performance: adults’ experiences in five countries. Health Aff. 2004;W4:487–503.Google Scholar
  26. 26.
    Vivancos R, Schelenz S, Loke YK. Internet treatment of sexually transmitted infections—a public health hazard? BMC Public Health. 2007;7(333). doi: 10.1186/1471-2458-7-333.
  27. 27.
    World Health Organisation. Drug- and multidrug-resistant tuberculosis (MDR-TB). Geneva: WHO; 2008. http://www.who.int/tb/challenges/mdr/en/index.html. Accessed 18 Oct 2010.
  28. 28.
    Baker J, Graham M, Davies B. Gym users and abuse of prescription drugs. J R Soc Med. 2006;99(7):331–2.PubMedCrossRefGoogle Scholar
  29. 29.
    Wertheimer A, Chaney M, Santella T. Counterfeit pharmaceuticals: current status and future projections. J Am Pharm Assoc. 2003;43(6):710–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Janie Sheridan
    • 1
    Email author
  • Fiona Kelly
    • 1
  • James Oughton
    • 2
  • Aula Al-Jubbawey
    • 1
  • Matthew Grey
    • 1
  • Shameel Hussein
    • 1
  • Edwardine Jayetileke
    • 1
  • Mehul Mehta
    • 1
  • Shriyash Nair
    • 1
  1. 1.The School of PharmacyUniversity of AucklandAucklandNew Zealand
  2. 2.MedsafeMinistry of HealthAucklandNew Zealand

Personalised recommendations